BIRC5 and cancer: Hence, TP53RK is emerging as a novel oncogene protein and therapeutic target against these cancers.[11, 36, 37, 38] Meanwhile, as an important component of the EKC/KEOPS complex that plays a central role in the synthesis of an essential tRNA modification, mutations of TP53RK cause GAMOS.[9] Our current research showed that TP53RK also functions to promote CKD kidney fibrosis and the profibrotic effect of TP53RK may rely on its regulation on Birc5, rather than p53.